98%
921
2 minutes
20
As the global population ages, the prevalence of osteoarthritis (OA) and joint disorders represent a major cause of disability and a significant public health burden. As current approaches for the management of OA focus on slowing the progression of disease, without repairing the underlying damage, novel treatments are necessary to improve outcomes. Over the past decade, autologous cell-based therapies using regenerative cells from fat or bone marrow have become a major focus of research into new approaches for the treatment of osteoarthritis and joint disorders. This review is intended to summarize findings in existing literature and identify gaps in knowledge that should be addressed in order to advance the field. We acknowledge that some findings may appear inconsistent, but show that apparent inconsistency in the literature may be attributable to variation in source of cells, stage of disease, method of delivery, follow-up time, evaluation method, and a number of other idiosyncrasies of individual studies. Still, a number of themes emerge from the data and some broader conclusions may be drawn that can be used to guide future studies. Ultimately, we conclude that there is overwhelming evidence demonstrating the safety of the autologous cell-based therapies. Furthermore, the data support the claim that regenerative cells are capable of reversing progression of OA. Regenerative cells, and especially those from adipose tissue, represent a promising new approach for the treatment of OA. Future work should include appropriate controls, and focus on answering questions related to dose required, appropriate delivery vehicle, and the impact of multiple treatments. Additionally, future studies should look at short and long-term effects of the treatments, and use functional as well as radiologic methods to evaluate efficacy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/asj/sjx015 | DOI Listing |
Regen Biomater
August 2025
Institute of Stomatology & Oral Maxilla Facial Key Laboratory, First Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
Reconstructing bone defects remains a significant challenge in clinical practice, driving the urgent need for advanced artificial grafts that simultaneously promote vascularization and osteogenesis. Addressing the critical trade-off between achieving high porosity/strength and effective bioactivity at safe ion doses, we incorporated strontium (Sr) into β-tricalcium phosphate (β-TCP) scaffolds with a triply periodic minimal surface (TPMS) structure using digital light processing (DLP)-based three-dimensional (3D) printing. Systematically screening Sr concentrations (0-10 mol%), we identified 10 mol% as optimal, leveraging the synergy between the biomimetic TPMS architecture, providing exceptional mechanical strength (up to 1.
View Article and Find Full Text PDFFront Bioeng Biotechnol
August 2025
Department of Orthopaedic and Reconstructive Surgery/Pediatric Orthopaedics, South China Hospital, Medical School, Shenzhen University, Shenzhen, China.
Distraction osteogenesis (DO) is an endogenous bone tissue engineering technique that harnesses the regenerative potential of bone and has been widely applied in limb lengthening, bone defect repair, and craniofacial reconstruction. The DO procedure consists of three distinct phases: the latency phase, the distraction phase, and the consolidation phase, each characterized by unique biological processes. In recent years, increasing attention has been directed toward the role of the immune system during DO.
View Article and Find Full Text PDFFront Neurosci
August 2025
First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Background: Spinal cord injury (SCI) often leads to severe motor and sensory impairments, and current treatment methods have not achieved complete neural repair. In recent years, exosomes have become a research focus in the treatment of nerve injuries due to their important roles in intercellular information transfer, immune regulation, and neural repair. Our study conducts a scientometric analysis to map the research landscape related to exosomes in SCI.
View Article and Find Full Text PDFFront Cell Neurosci
August 2025
Stem Cell Research Center, University of California, Irvine, Irvine, CA, United States.
Objective: To assess the safety and tolerability of intravitreal injection of human retinal progenitor cells (RPCs) at multiple dose levels in adults with non-syndromic retinitis pigmentosa (RP).
Design: A prospective, multicenter, open-label, single-arm, Phase I/IIa safety study of RPCs in adults with RP ( = 28). Two patient cohorts were studied: Cohort 1: BCVA no better than 20/200 and no worse than Hand Motions, and Cohort 2: BCVA no better than 20/40 and no worse than 20/200).
Vet World
July 2025
Laboratory of Theriogenology Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan.
Background And Aim: Mycotoxin contamination in poultry feed, particularly with aflatoxin B1 (AFB1) and ochratoxin A (OTA), poses significant threats to broiler health, meat quality, and consumer safety. Toxin binders are commonly used to mitigate these effects; however, their impact on endogenous stem cell activity and overall broiler performance remains underexplored. This study aimed to evaluate the efficacy of a commercial toxin binder in reducing AFB1 and OTA residues in broiler meat, inducing endogenous stem cell production, and improving growth and feed performance indices.
View Article and Find Full Text PDF